Brief: Nektar Therapeutics Receives Fast Track Designation For Rezpegaldesleukin For The Treatment Of Severe-To-Very Severe Alopecia Areata
29/07/2025 15:18
July 29 (Reuters) - Nektar Therapeutics NKTR.O: NEKTAR THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FOR REZPEGALDESLEUKIN FOR THE TREATMENT OF SEVERE-TO-VERY SEVERE ALOPECIA AREATA Source text: ID:nPn2pvf35a Further company coverage: NKTR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says